- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
BioMarin Pharmaceutical Inc
Add to PortfolioBMRN:US
38.6400 USD 0.1300 0.34%As of 20:10:00 ET on 05/25/2012.
Snapshot for BioMarin Pharmaceutical Inc (BMRN)
| Open: | 38.6100 | Day's Range: | 38.1600 - 38.8000 | Volume: | 792,216 | Bid: | 38.6400 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 38.5100 | 52wk Range: | 23.7350 - 39.2000 | 1-Yr Rtn: | +38.15% | Ask: | 38.6500 |
Key Statistics for BMRN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E (12/2012) | - |
| Earnings Per Share (USD) (ttm) | -0.6500 |
| Est. EPS (USD) (12/2012) | -0.5940 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 4,470.69 |
| Shares Outstanding (M) | 115.70 |
| Enterprise Value (M USD) (ttm) | 4,586.03 |
| Enterprise Value/EBITDA (ttm) | - |
| Price/Book (mrq) | 5.7905 |
| Price/Sale (ttm) | 9.7525 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 07/27/2012 |
More BMRN Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for BMRN
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for BMRN
BioMarin Pharmaceutical Inc. develops and commercializes therapeutic enzyme products. The Company has applied its proprietary enzyme technology to develop products for lysosomal storage diseases and for the treatment of serious burns. BioMarin's subsidiary provides analytical and diagnostic products and services in the area of carbohydrate biology.
| Pierre LapalmeChairman | Jean-Jacques BienaimeChief Executive Officer |
| Henry J FuchsExec VP/Chief Medical Officer | Stephen J Aselage "Steve"Exec VP/Chief Business Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page